Wolfe Research analyst Andy Chen downgraded Immunovant (IMVT) to Peer Perform from Outperform. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> Read More on IMVT: Immunovant price target lowered to $45 from $47 at Wells Fargo 3 Best Stocks to Buy Now, 11/21/2024, According to Top Analysts Immunovant’s Strategic Advances in Autoimmune Therapies Immunovant price target raised to $58 from $52 at Stifel Immunovant reports Q3 EPS (74c), consensus (60c) Disclaimer & DisclosureReport an Issue